A small pilot study suggests that rosiglitazone treatment for 6 months may improve attention and memory in patients with MCI and AD 82, but results from large-scale trials have been inconsistent 83, highlighting the need for further investigation into PPARγ's role in AD. The gene discussed is PPARG; the disease is Alzheimer disease.